文献速递糖尿病肥胖与代谢综合征

每周一次司美格鲁肽7.2 mg治疗肥胖合并2型糖尿病(STEP UP T2D)

Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-09-14

BACKGROUND: Semaglutide 2·4 mg is approved for weight management in adults with obesity or overweight in the presence of at least one obesity-related complication; however, many people with obesity and type 2 diabetes do not reach their bodyweight reduction goals with this dose.…

要点

  • 2-3级低血糖风险低,各剂量组与安慰剂相当

研究设计与样本

  • STEP UP T2D为随机、3b期、双盲对照、三臂平行组试验,在保加利亚、加拿大、匈牙利、波兰、葡萄牙、斯洛伐克、南非和美国的68家医院、专科诊所和医疗中心开展。

关键数值与推荐

  • 确证性次要终点包括体重下降≥10%、≥15%、≥20%的参与者比例,以及腰围(cm)和HbA1c(%)变化。
  • 2-3级低血糖风险低,各司美格鲁肽剂量组与安慰剂相当。

临床怎么用

  • 治疗应联合生活方式干预,疗程参考72周。

局限性

  • 研究未报告长期心血管结局。
  • 感觉异常的发生机制及长期影响尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Semaglutide 2·4 mg is approved for weight management in adults with obesity or overweight in the presence of at least one obesity-related complication; however, many people with obesity and type 2 diabetes do not reach their bodyweight reduction goals with this dose. We aimed to investigate the efficacy and safety of a new 7·2 mg maintenance dose of once-weekly subcutaneous semaglutide in people with obesity and type 2 diabetes. METHODS: STEP UP T2D was a randomised, phase 3b, double-blind controlled, three-arm, parallel-group trial conducted at 68 hospitals, specialist clinics, and medical centres in Bulgaria, Canada, Hungary, Poland, Portugal, Slovakia, South Africa, and the USA. Adults aged 18 years or older (BMI ≥30·0 kg/m2, HbA1c 7·0-10·0% [53-86 mmol/mol]) were randomly assigned (3:1:1) to receive once-weekly subcutaneous semaglutide 7·2 mg, 2·4 mg, or placebo, alongside a lifestyle intervention, for 72 weeks. Coprimary endpoints were the percentage change in bodyweight and the proportion of participants reaching a bodyweight reduction of 5% or greater with semaglutide 7·2 mg versus placebo. Confirmatory secondary endpoints were the proportion of participants reaching a bodyweight reduction of 10% or greater, 15% or greater, and 20% or greater, and changes in waist circumference (cm) and HbA1c (%) with semaglutide 7·2 mg versus placebo. Efficacy was assessed in all randomly assigned participants, and safety was assessed in all randomly assigned participants who received at least one dose of the trial product. This trial is registered with ClinicalTrials.gov (NCT05649137) and is now closed and completed. FINDINGS: Between Jan 4 and May 4, 2023, 512 participants were randomly assigned to receive semaglutide 7·2 mg (n=307), semaglutide 2·4 mg (n=103), or placebo (n=102). 265 (51·8%) of 512 participants were female, the mean age was 56 (SD 10) years, mean bodyweight was 110·1 (22·9) kg, mean BMI was 38·6 (7·1) kg/m2, and mean HbA1c was 8·1% (0·9). Compared with placebo, semaglutide 7·2 mg led to greater reductions in mean bodyweight (-13·2% vs -3·9%; estimated treatment difference [ETD] -9·3% [95% CI -11·0 to -7·7]; p<0·0001); more participants reaching bodyweight reductions of 5% or greater (odds ratio 10·0 [95% CI 6·0 to 16·9]; p<0·0001), 10% or greater (11·3 [5·9 to 21·4]; p<0·0001), 15% or greater (8·1 [3·7 to 17·7]; p<0·0001), and 20% or greater (12·3 [3·0 to 51·0]; p=0·0006); and reduced waist circumference (ETD -6·5 cm [95% CI -9·0 to -4·1]; p<0·0001) and HbA1c (ETD -1·5% [95% CI -1·8 to -1·2]; p<0·0001). Level 2-3 hypoglycaemia risk was low and comparable between semaglutide doses and placebo. Gastrointestinal events were reported by 163 (53·1%) of 307 participants with semaglutide 7·2 mg, 53 (51·5%) of 103 participants with semaglutide 2·4 mg, 26 (25·5%) of 102 participants with placebo; and serious adverse events were reported by 28 (9·1%) participants with semaglutide 7·2 mg, nine (8·7%) participants with semaglutide 2·4 mg, and nine (8·8%) participants with placebo. Dysaesthesia was more common with semaglutide 7·2 mg (58 [18·9%] of 307) versus 2·4 mg (five [4·9%] of 103) and placebo (none). INTERPRETATION: Among people with obesity and type 2 diabetes, semaglutide 7·2 mg was superior to placebo in reducing bodyweight, waist circumference, and HbA1c. Safety and tolerability were comparable between semaglutide 7·2 mg and 2·4 mg, except for the imbalance in dysaesthesia. FUNDING: Novo Nordisk. TRANSLATIONS: For the Bulgarian, Hungarian and Polish translations of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Lingvay I, Bergenheim SJ, Buse JB, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. PMID: 40961953. doi:10.1016/S2213-8587(25)00225-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。